Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting

Pharmacotherapy

Volumn 34, Issue 6, 2014, Pages 570-581

  Cea Soriano, Lucia ^a   Ruigõmez, Ana ^a   Johansson, Saga ^b   García Rodríguez, Luis A ^a  

^a Centro Español de Investigaciõn Farmacoepidemiolõgica ^*  (Spain)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

acid suppressive drugs; fractures; proton pump inhibitor

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; VERY ELDERLY; HIP FRACTURES; PRIMARY HEALTH CARE; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GREAT BRITAIN; HIP FRACTURES; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK;

EID: 84902154290     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1410     Document Type: Article

References (45)

1. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91.
2. 2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79: 76-83.
3. Yang YX, Lewis JD, Epstein S, Metz DC,. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
4. Corley DA, Kubo A, Zhao W, Quesenberry C,. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 1391: 93-101.
5. de Vries F, Cooper A, Cockle SM, van Staa TP, Cooper C,. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20: 1989-98.
6. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2011; 22: 903-10.
7. Kaye JA, Jick H,. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-9.
8. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83: 251-9.
9. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010; 170: 765-71.
10. Kwok CS, Yeong JK, Loke YK,. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011; 48: 768-76.
11. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K,. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106: 1209-18.
12. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ,. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778-81.
13. Yang YX, Metz DC,. Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115-27.
14. Mizunashi K, Furukawa Y, Katano K, Abe K,. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53: 21-5.
15. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS,. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984; 73: 640-7.
16. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE,. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008; 66: 103-8.
17. Langtry HD, Wilde MI,. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473-500.
18. Fitton A, Wiseman L,. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460-82.
19. Castot A, Bidault I, Dahan R, Efthymiou ML,. Evaluation of unexpected and toxic effects of omeprazole (Mopral) reported to the regional centers of pharmacovigilance during the first 22 postmarketing months [in French]. Therapie 1993; 48: 469-74.
20. Cea-Soriano L, Johansson S, Rodriguez LA,. Risk factors for falls with use of acid-suppressive drugs. Epidemiology 2013; 24: 600-7.
21. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB,. Incidence and mortality of hip fractures in the United States. JAMA 2009; 302: 1573-9.
22. van Staa TP, Dennison EM, Leufkens HG, Cooper C,. Epidemiology of fractures in England and Wales. Bone 2001; 29: 517-22.
23. Roland M, Guthrie B, Thome DC,. Primary medical care in the United Kingdom. J Am Board Fam Med 2012; 25 (suppl 1): S6-11.
24. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL,. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.
25. First Databank. MULTILEX for primary care. 2010. Available from http://www.fdbhealth.co.uk/multilex-overview/. Accessed September 2013.
26. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM,. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009; 18: 697-703.
27. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE,. Risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009; 18: 269-75.
28. Rodriguez LA, Ruigomez A, Wallander MA, Johansson S,. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology 2009; 20: 800-6.
29. Lustberg MB, Reinbolt RE, Shapiro CL,. Bone health in adult cancer survivorship. J Clin Oncol 2012; 30: 3665-74.
30. Guise TA,. Bone loss and fracture risk associated with cancer therapy. Oncologist 2006; 11: 1121-31.
31. Walker AM,. Case-control studies: sampling the source population. In:, Walker AM, ed. Observation and inference: an introduction to the methods of epidemiology. Chestnut Hill, MA: Epidemiology Resources Inc., 1991: 75-80.
32. Pearce N,. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993; 22: 1189-92.
33. Merriman NA, Putt ME, Metz DC, Yang YX,. Hip fracture risk in patients with a diagnosis of pernicious anemia. Gastroenterology 2010; 138: 1330-7.
34. Kanis JA, Johansson H, Oden A, McCloskey EV,. Assessment of fracture risk. Eur J Radiol 2009; 71: 392-7.
35. Souverein PC, Webb DJ, Petri H, Weil J, Van Staa TP, Egberts T,. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005; 46: 304-10.
36. Yoshimura N, Suzuki T, Hosoi T, Orimo H,. Epidemiology of hip fracture in Japan: incidence and risk factors. J Bone Miner Metab 2005; 23 (suppl): 78-80.
37. Armstrong ME, Spencer EA, Cairns BJ, et al. Body mass index and physical activity in relation to the incidence of hip fracture in postmenopausal women. J Bone Miner Res 2011; 26: 1330-8.
38. Tsiropoulos I, Andersen M, Nymark T, Lauritsen J, Gaist D, Hallas J,. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 2008; 49: 2092-9.
39. Vestergaard P, Hermann P, Jensen JE, Eiken P, Mosekilde L,. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int 2012; 23: 1255-65.
40. van Staa TP, Leufkens HG, Cooper C,. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone 2000; 27: 563-8.
41. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107: 1361-69.
42. Blak BT, Thompson M, Dattani H, Bourke A,. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011; 19: 251-5.
43. Moayyeri A,. The association between physical activity and osteoporotic fractures: a review of the evidence and implications for future research. Ann Epidemiol 2008; 18: 827-35.
44. Ralston SH,. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 2002; 87: 2460-6.
45. Jones R, Liker HR, Ducrotté P,. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007; 61: 1301-7.